Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
|---|---|---|---|---|---|
| CEA-B039 | Human | ClinMax™ Human Soluble CD38 ELISA Kit | |||
| CD8-H8214 | Human | Biotinylated Human CD38 Protein, Avitag™ |  |
|
|
| CD8-H82F5 | Human | Biotinylated Human CD38 Protein, Fc,Avitag™ (MALS verified) |  |
|
|
| CD8-HF255 | Human | FITC-Labeled Human CD38 Protein, Fc Tag |  |
|
|
| CD8-HF2H5 | Human | FITC-Labeled Human CD38 Protein, His Tag |  |
|
|
| MBC-K010 | Human | Human CD38-coupled Magnetic Beads | |||
| CD8-M5223 | Mouse | Mouse CD38 Protein, His Tag |  |
|
|
| CD8-C5223 | Cynomolgus | Cynomolgus CD38 Protein, His Tag |  |
|
|
| CD8-H5252 | Human | Human CD38 Protein, Llama IgG2b Fc Tag, low endotoxin |  |
|
|
| CD8-H5253 | Human | Human CD38 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| CD8-H5255 | Human | Human CD38 Protein, Fc Tag (MALS verified) |  |
|
|
| CD8-H82E7 | Human | Biotinylated Human CD38 Protein, Avitag™,His Tag |  |
|
|
| CD8-H5224 | Human | Human CD38 Protein, His Tag (MALS verified) |  |
|
Anti-CD38 mAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD38, His Tag (Cat. No. CD8-H5224) with an affinity constant of 4.98 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Daratumumab/Hyaluronidase-fihj | Approved | Johnson & Johnson Innovative Medicine | Darzalex Faspro, Darzquro | United States | Multiple Myeloma | Janssen Biotech Inc | 2020-05-01 | Peripheral Nervous System Diseases; Multiple Myeloma; Monoclonal Gammopathy of Undetermined Significance; Rejection of organ transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Amyloidosis; Rejection in heart transplantation | Details | |
| Isatuximab | SAR-650984 | Approved | Immunogen Inc | Sarclisa | United States | Multiple Myeloma | Sanofi-Aventis U.S. Llc | 2020-03-02 | Anemia, Aplastic; Leukemia, T-Cell; Carcinoma, Non-Small-Cell Lung; Macroglossia; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma; Nausea; Hepatomegaly; Gastrointestinal Hemorrhage; Satiety Response; Diarrhea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Hematologic Neoplasms; Anemia, Hemolytic, Autoimmune; Prostatic Neoplasms; Multiple Myeloma; Immunoglobulin Light-chain Amyloidosis; Purpura; Neoplasms; Smoldering Multiple Myeloma; Hodgkin Disease; Lymphadenopathy; Paraproteinemias; Constipation; Goiter, Nodular | Details |
| Daratumumab | JNJ-54767414 | Approved | Johnson & Johnson Innovative Medicine | Darzalex, 兆珂速, 兆珂 | United States | Multiple Myeloma | Janssen Biotech Inc | 2015-11-16 | Prostatic Neoplasms; POEMS Syndrome; Autoimmune Diseases of the Nervous System; Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Urologic Neoplasms; Amyloidosis; Lymphoma, Primary Effusion; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Kidney Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Glioblastoma; Immunoglobulin Light-chain Amyloidosis; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Smoldering Multiple Myeloma; Autoimmune Diseases; Paraproteinemias; Genital Neoplasms, Male; Carcinoma, Renal Cell; Purpura, Thrombocytopenic, Idiopathic | Details |
| Daratumumab/Hyaluronidase-fihj | Approved | Johnson & Johnson Innovative Medicine | Darzalex Faspro, Darzquro | United States | Multiple Myeloma | Janssen Biotech Inc | 2020-05-01 | Peripheral Nervous System Diseases; Multiple Myeloma; Monoclonal Gammopathy of Undetermined Significance; Rejection of organ transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Amyloidosis; Rejection in heart transplantation | Details | |
| Isatuximab | SAR-650984 | Approved | Immunogen Inc | Sarclisa | United States | Multiple Myeloma | Sanofi-Aventis U.S. Llc | 2020-03-02 | Anemia, Aplastic; Leukemia, T-Cell; Carcinoma, Non-Small-Cell Lung; Macroglossia; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma; Nausea; Hepatomegaly; Gastrointestinal Hemorrhage; Satiety Response; Diarrhea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Hematologic Neoplasms; Anemia, Hemolytic, Autoimmune; Prostatic Neoplasms; Multiple Myeloma; Immunoglobulin Light-chain Amyloidosis; Purpura; Neoplasms; Smoldering Multiple Myeloma; Hodgkin Disease; Lymphadenopathy; Paraproteinemias; Constipation; Goiter, Nodular | Details |
| Daratumumab | JNJ-54767414 | Approved | Johnson & Johnson Innovative Medicine | Darzalex, 兆珂速, 兆珂 | United States | Multiple Myeloma | Janssen Biotech Inc | 2015-11-16 | Prostatic Neoplasms; POEMS Syndrome; Autoimmune Diseases of the Nervous System; Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Urologic Neoplasms; Amyloidosis; Lymphoma, Primary Effusion; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Kidney Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Glioblastoma; Immunoglobulin Light-chain Amyloidosis; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Smoldering Multiple Myeloma; Autoimmune Diseases; Paraproteinemias; Genital Neoplasms, Male; Carcinoma, Renal Cell; Purpura, Thrombocytopenic, Idiopathic | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Felzartamab | MOR-03087; TJ-202; HBIB-202; MOR-202 | Phase 3 Clinical | Morphosys Ag | Glomerulonephritis, IGA; Lupus Nephritis; Multiple Myeloma; Glomerulonephritis, Membranous; Rejection of organ transplantation; Lupus Erythematosus, Systemic; Glomerulonephritis | Details |
| Daratumumab biosimilar (Biocad) | BCD-264 | Phase 3 Clinical | Biocad | Multiple Myeloma | Details |
| Mezagitamab | TAK-079 | Phase 2 Clinical | Takeda | Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Hematologic Neoplasms; Nephrosis; Glomerulonephritis, IGA; Kidney Diseases; Autoimmune Diseases; Multiple Myeloma; Lupus Erythematosus, Systemic; Thrombocytopenia; Glomerulonephritis | Details |
| STI-6129 | STI-6129; LNDS-1001 | Phase 2 Clinical | Sorrento Therapeutics Inc | Solid tumours; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| Modakafusp alfa | TEV-48573; TAK-573 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Neoplasms; Multiple Myeloma; Melanoma | Details |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma | Details |
| Anti-CD38 Antibody(Institute of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Purpura, Thrombocytopenic, Idiopathic; Antiphospholipid Syndrome | Details | |
| ISB-1442 | ISB 1442; ISB-1442 | Phase 2 Clinical | Ichnos Sciences Sa | Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| Erzotabart | GEN-3014 | Phase 2 Clinical | Genmab A/S | Lymphoma, Large B-Cell, Diffuse; Leukemia, Myeloid, Acute | Details |
| BHV-1100 | KP-1237; BHV-1100 | Phase 2 Clinical | Biohaven Pharmaceuticals Inc, Kleo Pharmaceuticals, PeptiDream Inc | Multiple Myeloma | Details |
| Lumrotatug | CM-313 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma | Details |
| 89Zr-DFO-daratumumab | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details | |
| CART-38 | CART-38 | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Leukemia, Myeloid, Acute | Details |
| 64Cu-DOTA-daratumumab | Phase 1 Clinical | City Of Hope National Medical Center | Multiple Myeloma | Details | |
| SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Shengyan Pharmaceutical Technology, Wuhan Union Hospital | Multiple Myeloma | Details | |
| Anti-CD38 chimeric antigen receptor T cell therapy(Yake Biotechnology) | CAR-T CD-38 | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| SCTC-21-C | SCTC21C; SCTC-21-C; SCT-C21C | Phase 1 Clinical | SinoCelltech Ltd | Hematologic Neoplasms | Details |
| CLL1 and CD38 Dual CAR-T therapy(Gracell Biotechnologies) | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd, The 920th Hospital Of Joint Logistics Support Force Of PLA | Leukemia, Myeloid, Acute | Details | |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| CD38-SADA:177 Lu-DOTA Drug Complex | Phase 1 Clinical | Y-Mabs Therapeutics Inc | Lymphoma, Non-Hodgkin | Details | |
| Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering) | Phase 1 Clinical | Hangzhou Jiuyuan Gene Engineering Co Ltd | Multiple Myeloma | Details | |
| CART-38（University of Pennsylvania） | CART-38 | Phase 1 Clinical | University Of Pennsylvania | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| ISB-2001 | ISB-2001 | Phase 1 Clinical | Ichnos Sciences Sa | Multiple Myeloma | Details |
| TNB-738 | TNB-738 | Phase 1 Clinical | TeneoFour Inc | Details | |
| GBR-1342 | GBR-1342; ISB-1342 | Phase 1 Clinical | Glenmark Pharmaceuticals Ltd | Multiple Myeloma | Details |
| XmAb-968 | XmAb968 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Leukemia, Promyelocytic, Acute | Details |
| SG-2501 | SG-2501 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Lymphoma | Details |
| XmAb-18968 | XmAb-18968 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Leukemia, Myeloid, Acute | Details |
| CID-103 | CID-103; TSK011010 | Phase 1 Clinical | Tusk Therapeutics Ltd | Multiple Myeloma | Details |
| Daratumumab biosimilar (Henlius) | HLX-15 | Phase 1 Clinical | Shanghai Henlius Biologics Co Ltd | Multiple Myeloma | Details |
| 211At-OKT10-B10 | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Multiple Myeloma | Details | |
| Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | Y-150; Y150 | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd | Multiple Myeloma | Details |
| Recombinant human anti-CD38 momoclonal antibody(Sumgen) | SG-301; SG301 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic | Details |
| Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) | Phase 1 Clinical | Celularity Inc, Sorrento Therapeutics Inc | Multiple Myeloma | Details | |
| Felzartamab | MOR-03087; TJ-202; HBIB-202; MOR-202 | Phase 3 Clinical | Morphosys Ag | Glomerulonephritis, IGA; Lupus Nephritis; Multiple Myeloma; Glomerulonephritis, Membranous; Rejection of organ transplantation; Lupus Erythematosus, Systemic; Glomerulonephritis | Details |
| Daratumumab biosimilar (Biocad) | BCD-264 | Phase 3 Clinical | Biocad | Multiple Myeloma | Details |
| Mezagitamab | TAK-079 | Phase 2 Clinical | Takeda | Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Hematologic Neoplasms; Nephrosis; Glomerulonephritis, IGA; Kidney Diseases; Autoimmune Diseases; Multiple Myeloma; Lupus Erythematosus, Systemic; Thrombocytopenia; Glomerulonephritis | Details |
| STI-6129 | STI-6129; LNDS-1001 | Phase 2 Clinical | Sorrento Therapeutics Inc | Solid tumours; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| Modakafusp alfa | TEV-48573; TAK-573 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Neoplasms; Multiple Myeloma; Melanoma | Details |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma | Details |
| Anti-CD38 Antibody(Institute of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Purpura, Thrombocytopenic, Idiopathic; Antiphospholipid Syndrome | Details | |
| ISB-1442 | ISB 1442; ISB-1442 | Phase 2 Clinical | Ichnos Sciences Sa | Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| Erzotabart | GEN-3014 | Phase 2 Clinical | Genmab A/S | Lymphoma, Large B-Cell, Diffuse; Leukemia, Myeloid, Acute | Details |
| BHV-1100 | KP-1237; BHV-1100 | Phase 2 Clinical | Biohaven Pharmaceuticals Inc, Kleo Pharmaceuticals, PeptiDream Inc | Multiple Myeloma | Details |
| Lumrotatug | CM-313 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma | Details |
| 89Zr-DFO-daratumumab | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details | |
| CART-38 | CART-38 | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Leukemia, Myeloid, Acute | Details |
| 64Cu-DOTA-daratumumab | Phase 1 Clinical | City Of Hope National Medical Center | Multiple Myeloma | Details | |
| SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Shengyan Pharmaceutical Technology, Wuhan Union Hospital | Multiple Myeloma | Details | |
| Anti-CD38 chimeric antigen receptor T cell therapy(Yake Biotechnology) | CAR-T CD-38 | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| SCTC-21-C | SCTC21C; SCTC-21-C; SCT-C21C | Phase 1 Clinical | SinoCelltech Ltd | Hematologic Neoplasms | Details |
| CLL1 and CD38 Dual CAR-T therapy(Gracell Biotechnologies) | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd, The 920th Hospital Of Joint Logistics Support Force Of PLA | Leukemia, Myeloid, Acute | Details | |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| CD38-SADA:177 Lu-DOTA Drug Complex | Phase 1 Clinical | Y-Mabs Therapeutics Inc | Lymphoma, Non-Hodgkin | Details | |
| Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering) | Phase 1 Clinical | Hangzhou Jiuyuan Gene Engineering Co Ltd | Multiple Myeloma | Details | |
| CART-38（University of Pennsylvania） | CART-38 | Phase 1 Clinical | University Of Pennsylvania | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| ISB-2001 | ISB-2001 | Phase 1 Clinical | Ichnos Sciences Sa | Multiple Myeloma | Details |
| TNB-738 | TNB-738 | Phase 1 Clinical | TeneoFour Inc | Details | |
| GBR-1342 | GBR-1342; ISB-1342 | Phase 1 Clinical | Glenmark Pharmaceuticals Ltd | Multiple Myeloma | Details |
| XmAb-968 | XmAb968 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Leukemia, Promyelocytic, Acute | Details |
| SG-2501 | SG-2501 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Lymphoma | Details |
| XmAb-18968 | XmAb-18968 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Leukemia, Myeloid, Acute | Details |
| CID-103 | CID-103; TSK011010 | Phase 1 Clinical | Tusk Therapeutics Ltd | Multiple Myeloma | Details |
| Daratumumab biosimilar (Henlius) | HLX-15 | Phase 1 Clinical | Shanghai Henlius Biologics Co Ltd | Multiple Myeloma | Details |
| 211At-OKT10-B10 | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Multiple Myeloma | Details | |
| Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | Y-150; Y150 | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd | Multiple Myeloma | Details |
| Recombinant human anti-CD38 momoclonal antibody(Sumgen) | SG-301; SG301 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic | Details |
| Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) | Phase 1 Clinical | Celularity Inc, Sorrento Therapeutics Inc | Multiple Myeloma | Details |
This web search service is supported by Google Inc.
A-Z
